208 related articles for article (PubMed ID: 9625683)
1. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial.
Essell JH; Schroeder MT; Harman GS; Halvorson R; Lew V; Callander N; Snyder M; Lewis SK; Allerton JP; Thompson JM
Ann Intern Med; 1998 Jun; 128(12 Pt 1):975-81. PubMed ID: 9625683
[TBL] [Abstract][Full Text] [Related]
2. Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients.
Essell JH; Thompson JM; Harman GS; Halvorson RD; Snyder MJ; Callander NS; Clement DJ
Bone Marrow Transplant; 1992 Oct; 10(4):367-72. PubMed ID: 1422493
[TBL] [Abstract][Full Text] [Related]
3. Interventions for prophylaxis of hepatic veno-occlusive disease in people undergoing haematopoietic stem cell transplantation.
Cheuk DK; Chiang AK; Ha SY; Chan GC
Cochrane Database Syst Rev; 2015 May; 2015(5):CD009311. PubMed ID: 26017019
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation.
Park SH; Lee MH; Lee H; Kim HS; Kim K; Kim WS; Jung CW; Im YH; Yoon SS; Kang WK; Park K; Park CH; Kim SW
Bone Marrow Transplant; 2002 Jan; 29(2):137-43. PubMed ID: 11850708
[TBL] [Abstract][Full Text] [Related]
5. Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide.
Essell JH; Thompson JM; Harman GS; Halvorson RD; Snyder MJ; Johnson RA; Rubinsak JR
Blood; 1992 May; 79(10):2784-8. PubMed ID: 1586725
[TBL] [Abstract][Full Text] [Related]
6. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
[TBL] [Abstract][Full Text] [Related]
7. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD.
Topolsky D; Crilley P; Styler MJ; Bulova S; Brodsky I; Marks DI
Bone Marrow Transplant; 1996 Apr; 17(4):549-54. PubMed ID: 8722353
[TBL] [Abstract][Full Text] [Related]
8. Ursodiol to prevent hepatic venoocclusive disease.
Comcowich SA; Spitzer TR; Tsunoda SM
Ann Pharmacother; 1997 Oct; 31(10):1249-52. PubMed ID: 9337452
[TBL] [Abstract][Full Text] [Related]
9. Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy.
Vaughan WP; Dennison JD; Reed EC; Klassen L; McGuire TR; Sanger WG; Kumar PP; Warkentin PI; Gordon BG; Bierman PJ
Bone Marrow Transplant; 1991 Dec; 8(6):489-95. PubMed ID: 1790429
[TBL] [Abstract][Full Text] [Related]
10. Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial.
Cordonnier C; Chevret S; Legrand M; Rafi H; Dhédin N; Lehmann B; Bassompierre F; Gluckman E;
Ann Intern Med; 2003 Jul; 139(1):8-18. PubMed ID: 12834313
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2).
Copelan EA; Biggs JC; Szer J; Thompson JM; Crilley P; Brodsky I; Klein JL; Kapoor N; Harman GS; Avalos BR
Semin Oncol; 1993 Aug; 20(4 Suppl 4):33-8; quiz 39. PubMed ID: 8342074
[TBL] [Abstract][Full Text] [Related]
12. Regimen-related toxicity of a busulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation.
Nevill TJ; Barnett MJ; Klingemann HG; Reece DE; Shepherd JD; Phillips GL
J Clin Oncol; 1991 Jul; 9(7):1224-32. PubMed ID: 2045863
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group.
Ringdén O; Ruutu T; Remberger M; Nikoskelainen J; Volin L; Vindeløv L; Parkkali T; Lenhoff S; Sallerfors B; Ljungman P
Blood; 1994 May; 83(9):2723-30. PubMed ID: 8167351
[TBL] [Abstract][Full Text] [Related]
14. How can we reduce hepatic veno-occlusive disease-related deaths after allogeneic stem cell transplantation?
Johnson DB; Savani BN
Exp Hematol; 2012 Jul; 40(7):513-7. PubMed ID: 22542577
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in chronic phase following preparation with busulfan and cyclophosphamide.
Galimberti M; Polchi P; Lucarelli G; Angelucci E; Baronciani D; Giardini C; Gaziev D; Erer B; Ripalti M; Rapa S
Bone Marrow Transplant; 1994 Feb; 13(2):197-201. PubMed ID: 8205089
[TBL] [Abstract][Full Text] [Related]
16. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia.
Jillella AP; Doria R; Khan K; Zelterman D; Ahmad YH; Smith BR; Holmes W; Becker P; Roberts KB; Rappeport JM
Bone Marrow Transplant; 1999 Jun; 23(11):1095-100. PubMed ID: 10382947
[TBL] [Abstract][Full Text] [Related]
17. The influence of early transplantation, age, GVHD prevention regimen, and other factors on outcome of allogeneic transplantation for CML following BuCy.
Copelan EA; Penza SL; Theil KS; Elder PJ; Bechtel TP; Tighe MB; Ezzone SA; Scholl MD; Belt PS; Young DC; Avalos BR
Bone Marrow Transplant; 2000 Nov; 26(10):1037-43. PubMed ID: 11108300
[TBL] [Abstract][Full Text] [Related]
18. [Severe hepatic veno-occlusive disease (VOD) which was successfully treated with supportive therapy, but subsequently developed late-recurrence].
Matsuoka S; Okamoto S; Ishida A; Wakui M; Watanabe R; Moriki T; Ikeda Y; Hirabayashi N
Rinsho Ketsueki; 1998 Feb; 39(2):139-45. PubMed ID: 9545827
[TBL] [Abstract][Full Text] [Related]
19. Coexisting or underlying risk factors of hepatic veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients receiving prophylaxis.
Gökce M; Kuskonmaz B; Cetin M; Uckan Cetinkaya D; Tuncer M
Exp Clin Transplant; 2013 Oct; 11(5):440-6. PubMed ID: 24128137
[TBL] [Abstract][Full Text] [Related]
20. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens.
Radich JP; Sanders JE; Buckner CD; Martin PJ; Petersen FB; Bensinger W; McDonald GB; Mori M; Schoch G; Hansen JA
J Clin Oncol; 1993 Feb; 11(2):304-13. PubMed ID: 8426208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
